Aprea Therapeutics Reports Early Clinical Proof-of-Concept for WEE1 Inhibitor APR-1051

Event summary

  • Aprea Therapeutics observed a partial response in a patient with PPP2R1A-mutated uterine serous carcinoma at the 150 mg dose of APR-1051 in the ACESOT-1051 trial.
  • The patient achieved a 50% reduction in target lesion size and a 90% decrease in CA-125 levels.
  • Dose escalation continues with the 220 mg cohort currently enrolling.
  • Multiple patients achieved stable disease with reductions in tumor burden at lower dose levels.

The big picture

Aprea Therapeutics' early clinical data for APR-1051 provides proof-of-concept for its WEE1 inhibitor in advanced solid tumors, particularly those with specific genomic alterations. The company's strategy of targeting cancers with mutations like PPP2R1A, FBXW7, and HPV-positive disease aligns with the broader industry trend of precision oncology. The potential dose-response trend and favorable safety profile observed in the ongoing trial reinforce the company's confidence in APR-1051 as a differentiated therapy.

What we're watching

Dose Optimization
The pace at which Aprea Therapeutics identifies the recommended Phase 2 dose for APR-1051 will determine the timeline for further clinical evaluation.
Patient Enrollment
Whether Aprea can sustain enrollment and observe similar clinical activity in additional patients, particularly those with HPV-positive disease.
Strategic Focus
How Aprea Therapeutics balances the development of APR-1051 with its other lead program, ATRN-119, in the context of limited resources.